Immune checkpoint inhibitors targeting programmed cell death 1 or its ligand, programmed cell death 1 ligand 1, (PD-1 or PD-L1, respectively) are active in many different tumor types and may modulate the immune response by impacting a common immune regulatory pathway. The gene discussed is CD274; the disease is neoplasm.